pharma · ALKEM
Alkem Laboratories
Alkem Laboratories: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹5,816.5
Price 2026-07-30
5 day
+3.25%
Short-term move
1 month
+4.43%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹67.8k Cr
inflow sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's NARROW LEADERSHIP regime affect Alkem Laboratories (ALKEM) in the pharma sector?”
Price chart
₹5,652
+15.54% over period
About Alkem Laboratories
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -6.7% over 14 days) — not a reliable pattern.
52-week position
Trading at 98% of 52-week high
Technicals
RSI 14
58.4
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
29.4
57th pct · 7 quarterly points (limited history)
P/B
4.9
ROE
17.6%
Moderate profitability — 17.6% ROE
Market cap
₹67.8k Cr
Revenue growth
1460.0% YoY
Promoter
62.9%
52-week range
₹4,716.2 – ₹5,933.5
98% of high
RSI (14)
58.4
uptrend
vs 50 DMA
Above
DMA ₹5,486.58
Coverage
100/100
HIGH
Quick Take
Alkem Laboratories: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹7,835 | +7.7% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,466.4 | +5.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,144.8 | -1.8% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,576.3 | +3.5% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| BIOCON Biocon | ₹425.35 | -2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,190.3 | -0.7% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,517 | +5.9% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| JBCHEPHARM J B Chemicals | ₹2,408.9 | +0.0% | 54.5 | 18.7% | -480% | ₹38.9k Cr |
| ALKEM Alkem Laboratories | ₹5,816.5 | +3.8% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
Key Watchpoints
Breaks above ₹6107 (+5%)
Trend reversal confirmation
Breaks below ₹5526 (-5%)
Further downside risk
PE reverts to median of 28.1 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing